Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roch Houot

Showing results (11-20 of 232) with videos related to

Pageof 24
Sort By:
La Revue Du Praticien|January 23, 2026
[Caring for carers to better care for patients]Sophie De Guibert, Roch Houot
Haematologica|July 15, 2018
Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapyMarie de Charette, Roch Houot
Oncoimmunology|November 20, 2012
Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibodyRoch Houot, Holbrook Kohrt, Ron Levy
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Hyperprogression upon immunotherapy: A chance for (hyper-)progressRoch Houot, Aurélien Marabelle, Stéphane Champiat
European Journal of Cancer (Oxford, England : 1990)|December 6, 2021
Disease-specific outcomes after chimeric antigen receptor T-cell therapyJean Lemoine, Samuel Vic, Roch Houot
Journal of Hematology & Oncology|November 23, 2021
Born to survive: how cancer cells resist CAR T cell therapyJean Lemoine, Marco Ruella, Roch Houot
JAMA Dermatology|November 24, 2017
Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel HypothesisGuillaume Manson, Aurélien Marabelle, Roch Houot
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell KillingJean Lemoine, Marco Ruella, Roch Houot
Bulletin Du Cancer|February 12, 2026
[Generations at work: From gaps to shared strength]Olivier Revol, Roch Houot, Emmanuel Gyan
Cancers|September 10, 2021
T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent AdvancesOndine Messéant, Roch Houot, Guillaume Manson
Pageof 24

Showing results (11-20 of 232) with videos related to

Sort By:
Pageof 24
La Revue Du Praticien|January 23, 2026
[Caring for carers to better care for patients]Sophie De Guibert, Roch Houot
Haematologica|July 15, 2018
Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapyMarie de Charette, Roch Houot
Oncoimmunology|November 20, 2012
Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibodyRoch Houot, Holbrook Kohrt, Ron Levy
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Hyperprogression upon immunotherapy: A chance for (hyper-)progressRoch Houot, Aurélien Marabelle, Stéphane Champiat
European Journal of Cancer (Oxford, England : 1990)|December 6, 2021
Disease-specific outcomes after chimeric antigen receptor T-cell therapyJean Lemoine, Samuel Vic, Roch Houot
Journal of Hematology & Oncology|November 23, 2021
Born to survive: how cancer cells resist CAR T cell therapyJean Lemoine, Marco Ruella, Roch Houot
JAMA Dermatology|November 24, 2017
Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel HypothesisGuillaume Manson, Aurélien Marabelle, Roch Houot
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell KillingJean Lemoine, Marco Ruella, Roch Houot
Bulletin Du Cancer|February 12, 2026
[Generations at work: From gaps to shared strength]Olivier Revol, Roch Houot, Emmanuel Gyan
Cancers|September 10, 2021
T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent AdvancesOndine Messéant, Roch Houot, Guillaume Manson
Pageof 24